Biocon shares slipped over 2 per cent on Thursday morning after the US health regulator issued six observations in Form 483 after pre-approval inspection of its insulin drug substance manufacturing facility in Bengaluru. “The USFDA concluded a pre-approval inspection of Biocon’s insulin drug substance manufacturing facility triggered by a New Drug Application submitted by the company’s insulin API customer,” the company said.
For more information on
stock tips and quick free trial click here >
911 133 9000 Visit
http://www.epicresearch.co
Connect with our social media sites
Posted in: Indian Market Tips
Email This
BlogThis!
Share to Facebook
22:37
Unknown
0 comments:
Post a Comment